vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Esperion Therapeutics, Inc.的1.1倍（$183.1M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -1.8%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
AMPH vs ESPR — 直观对比
营收规模更大
AMPH
是对方的1.1倍
$168.4M
营收增速更快
ESPR
高出145.6%
-1.8%
两年增速更快
ESPR
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $168.4M |
| 净利润 | $24.4M | — |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 50.6% |
| 净利率 | 13.3% | — |
| 营收同比 | -1.8% | 143.7% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHESPR
| Q4 25 | $183.1M | $168.4M | ||
| Q3 25 | $191.8M | $87.3M | ||
| Q2 25 | $174.4M | $82.4M | ||
| Q1 25 | $170.5M | $65.0M | ||
| Q4 24 | $186.5M | $69.1M | ||
| Q3 24 | $191.2M | $51.6M | ||
| Q2 24 | $182.4M | $73.8M | ||
| Q1 24 | $171.8M | $137.7M |
净利润AMPHESPR
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-31.3M | ||
| Q2 25 | $31.0M | $-12.7M | ||
| Q1 25 | $25.3M | $-40.5M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-29.5M | ||
| Q2 24 | $37.9M | $-61.9M | ||
| Q1 24 | $43.2M | $61.0M |
毛利率AMPHESPR
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHESPR
| Q4 25 | 19.4% | 50.6% | ||
| Q3 25 | 13.2% | -11.4% | ||
| Q2 25 | 24.2% | 8.6% | ||
| Q1 25 | 21.9% | -34.0% | ||
| Q4 24 | 24.2% | -6.4% | ||
| Q3 24 | 29.8% | -31.0% | ||
| Q2 24 | 30.3% | 3.5% | ||
| Q1 24 | 27.9% | 52.5% |
净利率AMPHESPR
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -35.9% | ||
| Q2 25 | 17.8% | -15.4% | ||
| Q1 25 | 14.8% | -62.2% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -57.2% | ||
| Q2 24 | 20.8% | -83.9% | ||
| Q1 24 | 25.1% | 44.3% |
每股收益（稀释后）AMPHESPR
| Q4 25 | $0.51 | $0.32 | ||
| Q3 25 | $0.37 | $-0.16 | ||
| Q2 25 | $0.64 | $-0.06 | ||
| Q1 25 | $0.51 | $-0.21 | ||
| Q4 24 | $0.74 | $-0.14 | ||
| Q3 24 | $0.78 | $-0.15 | ||
| Q2 24 | $0.73 | $-0.33 | ||
| Q1 24 | $0.81 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $167.9M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $-302.0M |
| 总资产 | $1.6B | $465.9M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHESPR
| Q4 25 | $282.8M | $167.9M | ||
| Q3 25 | $276.2M | $92.4M | ||
| Q2 25 | $231.8M | $86.1M | ||
| Q1 25 | $236.9M | $114.6M | ||
| Q4 24 | $221.6M | $144.8M | ||
| Q3 24 | $250.5M | $144.7M | ||
| Q2 24 | $217.8M | $189.3M | ||
| Q1 24 | $289.6M | $226.6M |
总债务AMPHESPR
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHESPR
| Q4 25 | $788.8M | $-302.0M | ||
| Q3 25 | $776.7M | $-451.4M | ||
| Q2 25 | $757.5M | $-433.5M | ||
| Q1 25 | $751.3M | $-426.2M | ||
| Q4 24 | $732.3M | $-388.7M | ||
| Q3 24 | $727.7M | $-370.2M | ||
| Q2 24 | $713.3M | $-344.2M | ||
| Q1 24 | $672.4M | $-294.3M |
总资产AMPHESPR
| Q4 25 | $1.6B | $465.9M | ||
| Q3 25 | $1.7B | $364.0M | ||
| Q2 25 | $1.6B | $347.1M | ||
| Q1 25 | $1.6B | $324.0M | ||
| Q4 24 | $1.6B | $343.8M | ||
| Q3 24 | $1.5B | $314.1M | ||
| Q2 24 | $1.5B | $352.3M | ||
| Q1 24 | $1.6B | $373.1M |
负债/权益比AMPHESPR
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHESPR
| Q4 25 | $32.9M | $45.2M | ||
| Q3 25 | $52.6M | $-4.3M | ||
| Q2 25 | $35.6M | $-31.4M | ||
| Q1 25 | $35.1M | $-22.6M | ||
| Q4 24 | $29.0M | $-35.0M | ||
| Q3 24 | $60.0M | $-35.3M | ||
| Q2 24 | $69.1M | $-7.2M | ||
| Q1 24 | $55.3M | $53.8M |
自由现金流AMPHESPR
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $-35.5M | ||
| Q2 24 | $63.1M | $-7.3M | ||
| Q1 24 | $46.5M | $53.8M |
自由现金流率AMPHESPR
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | -68.7% | ||
| Q2 24 | 34.6% | -9.9% | ||
| Q1 24 | 27.1% | 39.0% |
资本支出强度AMPHESPR
| Q4 25 | 4.5% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.1% |
现金转化率AMPHESPR
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
